Circulating Concentrations of Insulin Resistance-Associated Hepatokines, Selenoprotein P and Leukocyte Cell-Derived Chemotaxin 2, during an Oral Glucose Tolerance Test in Humans

Access this Article

Author(s)

    • Mohri Kensuke Mohri Kensuke
    • Department of Endocrinology and Metabolism, Kanazawa University Graduate School of Medical Sciences|Department of System Biology, Kanazawa University Graduate School of Medical Sciences
    • Ishii Kiyo-aki Misu Hirofumi
    • Department of Endocrinology and Metabolism, Kanazawa University Graduate School of Medical Sciences|PRESTO, Japan Science and Technology Agency
    • Kikuchi Akihiro Takayama Hiroaki
    • Department of Endocrinology and Metabolism, Kanazawa University Graduate School of Medical Sciences|Department of System Biology, Kanazawa University Graduate School of Medical Sciences
    • Lan Fei Ishii Kiyo-aki
    • Department of Endocrinology and Metabolism, Kanazawa University Graduate School of Medical Sciences|Department of System Biology, Kanazawa University Graduate School of Medical Sciences
    • Takeshita Yumie Lan Fei
    • Department of System Biology, Kanazawa University Graduate School of Medical Sciences|Department of Endocrinology and Metabolism, Chengdu First People's Hospital
    • Saito Yoshiro Enyama Yasufumi
    • Department of Endocrinology and Metabolism, Kanazawa University Graduate School of Medical Sciences|Department of System Biology, Kanazawa University Graduate School of Medical Sciences
    • Takamura Toshinari Saito Yoshiro
    • Laboratory of Molecular and Biochemical Toxicology, Graduate School of Pharmaceutical Sciences, Tohoku University|Department of Medical Life Systems, Faculty of Life and Medical Sciences, Doshisha University

Abstract

<p>A hepatokine is a collective term for liver-derived secretory factors whose previously-unrecognized functions have been recently elucidated. We have rediscovered selenoprotein P (SeP) and leukocyte cell-derived chemotaxin 2 (LECT2) as hepatokines that are involved in the development of insulin resistance and hyperglycemia. The aim of this study was to determine whether and, if so, how oral glucose loading alters the two hepatokines in humans. We measured concentrations of serum SeP and plasma LECT2 during 75 g oral glucose tolerance test (OGTT) (<i>n</i> = 20) in people with various degrees of glucose tolerance. In OGTT, concentrations of both serum SeP and plasma LECT2 decreased at 120 min compared with the baseline values, irrespective of the severity of glucose intolerance. Decrement of serum SeP during OGTT showed no correlations to the clinical parameters associated with insulin resistance or insulin secretion. In multiple stepwise regression analyses, plasma cortisol was selected as the variable to explain the changes in plasma concentrations of LECT2. The current data reveal the acute inhibitory actions of oral intake of glucose on circulating SeP and LECT2 in humans, irrespective of the severity of glucose intolerance. This study suggests that circulating SeP is regulated by the unknown clinical factors other than insulin and glucose during OGTT.</p>

Journal

  • Biological and Pharmaceutical Bulletin

    Biological and Pharmaceutical Bulletin 42(3), 373-378, 2019

    The Pharmaceutical Society of Japan

Codes

  • NII Article ID (NAID)
    130007607371
  • NII NACSIS-CAT ID (NCID)
    AA10885497
  • Text Lang
    ENG
  • ISSN
    0918-6158
  • NDL Article ID
    029543538
  • NDL Call No.
    Z53-V41
  • Data Source
    NDL  J-STAGE 
Page Top